Photodynamic Therapy Market Report 2026

The photodynamic therapy market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising prevalence of skin cancer and precancerous lesions, increasing use of minimally invasive therapies, early clinical validation of photosensitizers, growing awareness of non-surgical treatment options, availability of laser-based medical devices.

The photodynamic therapy market size is expected to see strong growth in the next few years. It will grow to $2.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to advancements in novel photosensitizer formulations, expanding applications beyond oncology, increasing demand for outpatient therapies, growing investment in cancer treatment infrastructure, rising preference for targeted and precision therapies. Major trends in the forecast period include expansion of photodynamic therapy in oncology, growing adoption in dermatology and aesthetic treatments, development of next-generation photosensitizers, shift toward minimally invasive cancer treatments, rising use of combination therapy approaches.

The rising prevalence of skin cancer is expected to drive the growth of the photodynamic therapy (PDT) market. Skin cancer is the most common form of cancer worldwide, with melanoma accounting for only about 1% of cases but responsible for a significant proportion of skin cancer-related deaths. Photodynamic therapy employs a combination of a light-activated sensitizing agent and intense light to selectively destroy cancer cells. The sensitizing agent is applied topically to the affected area, enabling precise targeting of malignant cells while minimizing damage to surrounding healthy tissue. For instance, in 2023, according to Cancer Australia, an Australia-based government agency, approximately 8,257 new cases of melanoma were diagnosed, representing 2.6% of all cancer-related deaths. Therefore, the increasing prevalence of skin cancer is expected to fuel the growth of the PDT market in the coming years.

Major companies in the photodynamic therapy market are focusing on clinical trials to evaluate PDT in combination with novel drugs for improved therapeutic outcomes. Photodynamic therapy involves using light-activated compounds to selectively target and destroy diseased or malignant cells. For example, in February 2024, Kintara Therapeutics, a US-based biotechnology company, initiated a clinical trial for its REM-001 therapy targeting cutaneous metastatic breast cancer (CMBC). The open-label study (NCT05374915) involves 15 patients and evaluates the second-generation PDT agent REM-001 at a 0.8 mg dose. The trial is designed to optimize protocols ahead of a Phase 3 study, with primary endpoints assessing complete and partial responses within 24 weeks and the Best Overall Objective Response Rate (bORR) in treated fields.

In February 2023, Omni Partners LLP, a UK-based investment management firm, acquired Aesthetic Technology Ltd for an undisclosed amount. This acquisition aims to advance healthcare technologies, particularly in medical and aesthetic treatments. Aesthetic Technology Ltd is a UK-based manufacturer specializing in innovative energy-based devices for medical, aesthetic, and cosmetic applications, supporting the development of next-generation PDT solutions.

Major companies operating in the photodynamic therapy market are Galderma S.A., Bausch Health, Lumenis Ltd., Biofrontera, Modlight Inc., PhotoMedex Inc., Soligenix Inc., Quest PharmaTech Inc., Theralase Technologies Inc., Quantel Medical, Axcan Pharma, Sihealth, MediGlobus, Steba Biotech, Ambicare Health, Nuovo Therapy, Pharmstandard, Rusatom Healthcare, Hologic Inc., Dusa Pharmaceuticals, PDT Pharma Indústria e Comércio de Produtos Farmacêuticos, MMOptics Ltd, Global Healthcare Solutions Perú, DMC Equipmentos LTDA, Biolite, SyMed LLC, Alma Lasers, Candela Medica, Velt International Group Inc.

North America was the largest region in the photodynamic therapy market in 2025. The regions covered in the photodynamic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the photodynamic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the photodynamic therapy market by increasing costs of imported medical devices, laser systems, and specialized components used in PDT equipment and light sources. Higher tariffs have particularly affected device manufacturers and treatment centers in regions dependent on cross-border supply chains, such as asia-pacific and parts of europe. Increased equipment prices have slowed adoption in cost-sensitive healthcare settings, especially smaller dermatology clinics and hospitals. However, tariffs have also encouraged local manufacturing, regional sourcing of devices, and investment in domestic production capabilities, supporting long-term supply chain resilience.

The photodynamic therapy market research report is one of a series of new reports that provides photodynamic therapy market statistics, including photodynamic therapy industry global market size, regional shares, competitors with a photodynamic therapy market share, detailed photodynamic therapy market segments, market trends and opportunities, and any further data you may need to thrive in the photodynamic therapy industry. This photodynamic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Photodynamic therapy (PDT) is a treatment that uses a combination of a light source and a light-sensitive medication to destroy abnormal cells. It is employed to treat certain eye and skin conditions, as well as specific types of cancers. PDT works in two stages: a photosensitizing drug is administered and then activated by light energy to target and eliminate cancerous or precancerous cells.

The main types of products in the photodynamic therapy market are drugs and devices. PDT drugs are light-sensitive medications that are activated by specific types of light to destroy abnormal cells and treat various diseases. PDT devices include lamps, LED systems, and other equipment that emit light to activate the drugs. Photodynamic therapy is used for conditions such as acne, actinic keratosis, cancer, psoriasis, and others, and is applied in sectors including cosmetic and dermatology clinics, hospitals, cancer treatment centers, and other healthcare settings.

The photodynamic therapy market includes revenues earned by entities by treating actinic keratoses and superficial basal cell carcinomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.